273 related articles for article (PubMed ID: 18801766)
41. Intravitreal anti-VEGF versus photodynamic therapy with verteporfin for treatment of myopic choroidal neovascularization.
Yoon JU; Byun YJ; Koh HJ
Retina; 2010 Mar; 30(3):418-24. PubMed ID: 20094012
[TBL] [Abstract][Full Text] [Related]
42. Intravitreal ranibizumab for the treatment of inflammatory choroidal neovascularization.
Rouvas A; Petrou P; Douvali M; Ntouraki A; Vergados I; Georgalas I; Markomichelakis N
Retina; 2011 May; 31(5):871-9. PubMed ID: 21358461
[TBL] [Abstract][Full Text] [Related]
43. Bevacizumab vs photodynamic therapy for choroidal neovascularization in multifocal choroiditis.
Parodi MB; Iacono P; Kontadakis DS; Zucchiatti I; Cascavilla ML; Bandello F
Arch Ophthalmol; 2010 Sep; 128(9):1100-3. PubMed ID: 20837791
[TBL] [Abstract][Full Text] [Related]
44. Laser photocoagulation, photodynamic therapy, and intravitreal bevacizumab for the treatment of juxtafoveal choroidal neovascularization secondary to pathologic myopia.
Parodi MB; Iacono P; Papayannis A; Sheth S; Bandello F
Arch Ophthalmol; 2010 Apr; 128(4):437-42. PubMed ID: 20142520
[TBL] [Abstract][Full Text] [Related]
45. Intravitreal bevacizumab (Avastin) treatment of neovascular age-related macular degeneration.
Emerson MV; Lauer AK; Flaxel CJ; Wilson DJ; Francis PJ; Stout JT; Emerson GG; Schlesinger TK; Nolte SK; Klein ML
Retina; 2007; 27(4):439-44. PubMed ID: 17420695
[TBL] [Abstract][Full Text] [Related]
46. Intravitreal bevacizumab to treat myopic choroidal neovascularization: 2-year outcome.
Ruiz-Moreno JM; Montero JA
Graefes Arch Clin Exp Ophthalmol; 2010 Jul; 248(7):937-41. PubMed ID: 20221624
[TBL] [Abstract][Full Text] [Related]
47. Intravitreal bevacizumab for neovascular age-related macular degeneration with or without prior treatment with photodynamic therapy: one-year results.
Carneiro AM; Falcão MS; Brandão EM; Falcão-Reis FM
Retina; 2010 Jan; 30(1):85-92. PubMed ID: 20010320
[TBL] [Abstract][Full Text] [Related]
48. Intravitreal bevacizumab for choroidal neovascularization secondary to presumed ocular histoplasmosis syndrome.
Ehrlich R; Ciulla TA; Maturi R; Kheradiya NS; Hrisomalos N; Shulman S; Guess MG; Coyle E; Harris A
Retina; 2009; 29(10):1418-23. PubMed ID: 19898179
[TBL] [Abstract][Full Text] [Related]
49. Primary intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration: results of the Pan-American Collaborative Retina Study Group at 12 months follow-up.
Arevalo JF; Fromow-Guerra J; Sanchez JG; Maia M; Berrocal MH; Wu L; Saravia MJ; Costa RA;
Retina; 2008; 28(10):1387-94. PubMed ID: 18827735
[TBL] [Abstract][Full Text] [Related]
50. Intravitreal bevacizumab for treatment of subfoveal idiopathic choroidal neovascularization: results of a 1-year prospective trial.
Zhang H; Liu ZL; Sun P; Gu F
Am J Ophthalmol; 2012 Feb; 153(2):300-306.e1. PubMed ID: 21982109
[TBL] [Abstract][Full Text] [Related]
51. Prognostic factors for visual outcome after intravitreal anti-VEGF injection for naive myopic choroidal neovascularization.
Yoon JU; Kim YM; Lee SJ; Byun YJ; Koh HJ
Retina; 2012 May; 32(5):949-55. PubMed ID: 22534553
[TBL] [Abstract][Full Text] [Related]
52. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration in treatment-naive patients.
Pedersen KB; Sjølie AK; Møller F
Acta Ophthalmol; 2009 Nov; 87(7):714-9. PubMed ID: 19094171
[TBL] [Abstract][Full Text] [Related]
53. One-year outcomes of less frequent bevacizumab in age-related macular degeneration.
Sonmez K; Sonmez PA; Ozkan SS; Atmaca LS
Retina; 2011 Apr; 31(4):645-53. PubMed ID: 21358363
[TBL] [Abstract][Full Text] [Related]
54. Intravitreal bevacizumab combined with photodynamic therapy for the treatment of occult choroidal neovascularization associated with serous pigment epithelium detachment in age-related macular degeneration.
Ladas ID; Kotsolis AI; Papakostas TD; Rouvas AA; Karagiannis DA; Vergados I
Retina; 2007 Sep; 27(7):891-6. PubMed ID: 17891013
[TBL] [Abstract][Full Text] [Related]
55. Treatment of neovascular age-related macular degeneration with intravitreal bevacizumab: efficacy of three consecutive monthly injections.
Melamud A; Stinnett S; Fekrat S
Am J Ophthalmol; 2008 Jul; 146(1):91-5. PubMed ID: 18455144
[TBL] [Abstract][Full Text] [Related]
56. Comparison between one injection and three monthly injections of intravitreal bevacizumab for myopic choroidal neovascularization.
Niwa Y; Sawada O; Miyake T; Kakinoki M; Sawada T; Kawamura H; Ohji M
Ophthalmic Res; 2012; 47(3):135-40. PubMed ID: 22042059
[TBL] [Abstract][Full Text] [Related]
57. Intravitreal bevacizumab (Avastin) treatment of choroidal neovascularisation in patients with angioid streaks.
Wiegand TW; Rogers AH; McCabe F; Reichel E; Duker JS
Br J Ophthalmol; 2009 Jan; 93(1):47-51. PubMed ID: 18971238
[TBL] [Abstract][Full Text] [Related]
58. Intravitreal bevacizumab for the treatment of choroidal neovascularization associated with pathological myopia.
Rhéaume MA; Sebag M
Can J Ophthalmol; 2008 Oct; 43(5):576-80. PubMed ID: 18982035
[TBL] [Abstract][Full Text] [Related]
59. [Treatment of high myopic choroidal neovascularisation with intravitreal bevacizumab].
Mathieu B; Isaico R; Ramel JC; Bron AM; Creuzot-Garcher C
J Fr Ophtalmol; 2014 Jan; 37(1):54-7. PubMed ID: 24210931
[TBL] [Abstract][Full Text] [Related]
60. [Efficacy of three intravitreal injections of bevacizumab in the treatment of exudative age-related macular degeneration].
Bidot ML; Malvitte L; Bidot S; Bron A; Creuzot-Garcher C
J Fr Ophtalmol; 2011 Jun; 34(6):376-81. PubMed ID: 21550687
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
